Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved May 2001

Specific Treatments:

Thyroid disease; Hypothyroidism

Therapeutic Areas

General Information

Levoxyl has been approved for use as a replacement therapy for any form of diminished or absent thyroid function and as a means of suppressing pituitary secretion of TSH in euthyroid subjects to treat or prevent goiters. Levoxyl is available in tablet formulation, in 12 different color-coded strengths.

About 20 million Americans suffer from some form of thyroid disease and over 13 million subjects in the United States rely on hormone replacement therapy, which is usually taken for life, for treatment.

Clinical Results

Levoxyl has been prescribed as a thyroid hormone replacement therapy for the past 13 years. Due to an FDA ruling in 1997, all companies manufacturing levothyroxine sodium drugs were required to submit new drug applications in order to continue marketing these products.

Side Effects

Adverse events associated with the use of levothyroxine sodium may include (but are not limited to) the following:

  • Overdose may induce hyperthyroidism
  • Headache
  • Skin rash or hives
  • Sleepiness
  • Weight gain or loss
  • Nervousness

Mechanism of Action

Levoxyl contains synthetic crystalline levothyroxine sodium, which is the principal hormone secreted by the thyroid gland. Thyroid hormones are designed to regulate the metabolic rate of most body tissues.

Additional Information

For additional information on Levoxyl, please visit Jones Pharma.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation